阿斯利康上季收入勝預期 放棄非牟利出售疫苗
英國藥廠阿斯利康(AstraZeneca)(AZN.US) 第三季按固定匯率計算銷售急升28%至99億美元,高於市場普遍預期的96億美元。不包括新冠疫苗在內銷售增長17%,受惠於腫瘤藥物需求以及新興市場的增長,以及阿斯利康以390億美元收購的罕見疾病公司Alexion Pharmaceuticals。
在剔除與Alexion整合所帶來的一次性開支後,調整後每股盈利爲1.08美元,低於分析師平均預期的1.24美元。
第三季新冠疫苗銷售額爲10億美元,阿斯利康表示將不再以非牟利形式出售新冠疫苗,會將第四季疫苗銷售收益用來投資研發新冠抗體治療。
阿斯利康維持全年每股核心盈利介乎5.05至5.4美元,估計收入將有中至高雙位數增長,若剔除新冠疫苗後則有低雙位數增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.